Asia Pacific In Vitro Diagnostics Market

The APAC in vitro diagnostics (IVD) market is expected to grow from USD 29.27 billion in 2026 to USD 45.11 billion by 2031, representing a CAGR of 9.0% over the forecast period. The ongoing development of healthcare systems throughout the region, which is enhancing access to diagnostic services, supports market expansion. Since older adults typically require ongoing medical evaluations, the region's aging population is also contributing to increased testing needs. Additionally, diagnostic tests are being used more frequently for disease management and follow-up due to the rising prevalence of chronic health conditions. The APAC IVD market is steadily expanding as a result of these broad demographic and healthcare developments.

In September 2024, Sysmex Corporation (Japan) introduced a new assay kit specifically designed for its Automated Blood Coagulation Analyzers, the CN-6500 and CN-3500. This product includes HISCL Series technology, which improves the accuracy and efficiency of coagulation testing.

To know about the assumptions considered for the study download the pdf brochure

In July 2024, Beckman Coulter, Inc. (a subsidiary of Danaher Corporation (US) entered into a collaboration with Fujirebio (Japan) to advance the development of blood-based biomarkers for Alzheimer’s disease. The partnership aims to identify new biomarkers and improve existing assays, which will support the detection of pathology.

The key players in this market F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Danaher Corporation (US), Sysmex Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., (China)., Siemens Healthineers AG (Germany), bioMérieux (France), Illumina, Inc. (US), Becton, Dickinson and Company (US), and QuidelOrtho Corporation (US) among others. These players have employed various organic and inorganic growth strategies, including collaborations, acquisitions, product launches, partnerships, agreements, and expansions, to strengthen their footprint and capture a greater share of the APAC in vitro diagnostics market.

F. Hoffmann-La Roche Ltd (Switzerland) outperforms in the APAC in vitro diagnostics market in large part due to its wide range of high-performance molecular, immunoassay, and clinical chemistry products, which are very much in use in hospitals, clinics, and clinical labs. Additionally, the company has a very strong distribution network at its disposal and is committed to implementing automated, integrated platforms that support high-throughput workflows and consistent diagnostic results.

Abbott is a dominant player in the APAC in vitro diagnostics field, which it has achieved through its wide presence in point-of-care and rapid testing solutions. The company offers user-friendly platforms and a wide array of test menus, which in turn enable quick clinical decision-making, making it a preferred choice in healthcare settings. Abbott is also at the forefront in terms of R&D, which in turn plays a role in improving and expanding its diagnostic portfolio.

Market Ranking

Some of the important players in the APAC in vitro diagnostics market include F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Danaher Corporation (US), Sysmex Corporation (Japan), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China). They have a diverse product portfolio as well as continuous technology improvements. Roche has established a strong reputation in the fields of molecular diagnostics, automation platforms, and high-throughput testing solutions, resulting in applications for some of the broadest clinical uses worldwide. The presence of Abbott in the region is significantly enhanced by a wide range of offerings in point-of-care testing, immunoassays, and clinical chemistry systems designed to achieve rapid and reliable results. Through its key subsidiaries, Danaher contributes to the development of advanced diagnostic instruments, reagents, and integrated workflow technologies. Sysmex deals in hematology analyzers, coagulation analyzers, and many other analyzers, which enjoy a good reputation for their platforms built for high-volume operation in the laboratory. Mindray has been pushing deeper into APAC through scalable testing systems and an expanding portfolio of IVD products tailored to different healthcare settings. Altogether, these companies are strongly influencing the competitive landscape of the APAC IVD market.

Related Reports:

APAC In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com